Kathryn Waller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kathryn Waller has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Chaz Mein
2 shared publicationsIris Gines Mir
2 shared publications- James Boot
The Francis Crick Institute, London NW1 1AT, UK
2 shared publications James Hallimond Brindley
2 shared publications- John Dustin Loy
Nebraska Veterinary Diagnostics Center, School of Veterinary Medicine and Biomedical Sciences, University of Nebraska–Lincoln, Lincoln, NE, USA
2 shared publications Kalpana Devalia
2 shared publications
Latest Publications
- 20 July 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 78, S740
Toll-like receptor 5 signalling mediates pro-inflammatory and fibrogenic responses in non-alcoholic steatohepatitis (NASH)
- 20 July 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 78, S740
Toll-like receptor 5 signalling mediates pro-inflammatory and fibrogenic responses in non-alcoholic steatohepatitis (NASH)
O23 Toll-like receptor 5 signalling mediates pro-inflammatory and fibrogenic responses in non-alcoholic steatohepatitis (NASH)
Introduction Non-alcoholic steatohepatitis (NASH) is a common, progressive inflammatory liver condition with no approved therapies. Hepatocyte lipotoxicity results in inflammation, immune (T cell) infiltration and stellate cell activation leading to fibrosis. Hepatic Toll-like receptors (TLR) sense gut-derived inflammatory signals such as lipopolysaccharide (via TLR4) and flagellin (TLR5) and may represent therapeutic targets in NASH. Flagellin and TLR5 have been implicated in murine NASH models and here we test the hypothesis that this pathway plays a pathogenic role in human disease. Methods Plasma TLR5 binding capacity and flagellin, stool Flic gene load (shotgun metagenomics sequencing) and hepatic TLR5 gene expression were measured in samples from 139 patients and 24 controls recruited from outpatient clinics and elective bariatric surgery. Lipotoxicity was modelled in vitro using oleic (1mM) and palmitic (0.5mM) acid in human hepatocyte-like (HepG2) and stellate (LX2) cells. Results Compared to controls, plasma TLR5-binding capacity was increased in advanced NASH fibrosis but not earlier stages of disease (TLR4-binding increased at all disease stages) as was flagellin concentration (538.3v 745.8pg/ml,p=0.004) which normalised in samples taken median 83 days following bariatric surgery (n=20, p=0.005). Stool Flic gene expression and hepatic TLR5 (but not TLR2 or TLR4) expression were increased in NASH, along with markers of intestinal permeability (FABP2, D-lactate). In vitro, TLR5 inhibition attenuated toxic lipid-mediated IL8 protein expression (all pConclusions TLR5 signalling is activated in human NASH, reverses following bariatric surgery and is associated with mechanisms of lipid-mediated inflammation and stellate cell activation. This pathway has potential as a novel therapeutic target in NASH.
O23 Toll-like receptor 5 signalling mediates pro-inflammatory and fibrogenic responses in non-alcoholic steatohepatitis (NASH)
Introduction Non-alcoholic steatohepatitis (NASH) is a common, progressive inflammatory liver condition with no approved therapies. Hepatocyte lipotoxicity results in inflammation, immune (T cell) infiltration and stellate cell activation leading to fibrosis. Hepatic Toll-like receptors (TLR) sense gut-derived inflammatory signals such as lipopolysaccharide (via TLR4) and flagellin (TLR5) and may represent therapeutic targets in NASH. Flagellin and TLR5 have been implicated in murine NASH models and here we test the hypothesis that this pathway plays a pathogenic role in human disease. Methods Plasma TLR5 binding capacity and flagellin, stool Flic gene load (shotgun metagenomics sequencing) and hepatic TLR5 gene expression were measured in samples from 139 patients and 24 controls recruited from outpatient clinics and elective bariatric surgery. Lipotoxicity was modelled in vitro using oleic (1mM) and palmitic (0.5mM) acid in human hepatocyte-like (HepG2) and stellate (LX2) cells. Results Compared to controls, plasma TLR5-binding capacity was increased in advanced NASH fibrosis but not earlier stages of disease (TLR4-binding increased at all disease stages) as was flagellin concentration (538.3v 745.8pg/ml,p=0.004) which normalised in samples taken median 83 days following bariatric surgery (n=20, p=0.005). Stool Flic gene expression and hepatic TLR5 (but not TLR2 or TLR4) expression were increased in NASH, along with markers of intestinal permeability (FABP2, D-lactate). In vitro, TLR5 inhibition attenuated toxic lipid-mediated IL8 protein expression (all pConclusions TLR5 signalling is activated in human NASH, reverses following bariatric surgery and is associated with mechanisms of lipid-mediated inflammation and stellate cell activation. This pathway has potential as a novel therapeutic target in NASH.
- Open Access
- 5 April 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (7) , 2319-2330
G protein–coupled receptor kinase 5 regulates thrombin signaling in platelets via PAR-1
The interindividual variation in the functional response of platelets to activation by agonists is heritable. Genome-wide association studies (GWASs) of quantitative measures of platelet function have identified fewer than 20 distinctly associated variants, some with unknown mechanisms. Here, we report GWASs of pathway-specific functional responses to agonism by adenosine 5′-diphosphate, a glycoprotein VI–specific collagen mimetic, and thrombin receptor-agonist peptides, each specific to 1 of the G protein–coupled receptors PAR-1 and PAR-4, in subsets of 1562 individuals. We identified an association (P = 2.75 × 10−40) between a common intronic variant, rs10886430, in the G protein–coupled receptor kinase 5 gene (GRK5) and the sensitivity of platelets to activate through PAR-1. The variant resides in a megakaryocyte-specific enhancer that is bound by the transcription factors GATA1 and MEIS1. The minor allele (G) is associated with fewer GRK5 transcripts in platelets and the greater sensitivity of platelets to activate through PAR-1. We show that thrombin-mediated activation of human platelets causes binding of GRK5 to PAR-1 and that deletion of the mouse homolog Grk5 enhances thrombin-induced platelet activation sensitivity and increases platelet accumulation at the site of vascular injury. This corroborates evidence that the human G allele of rs10886430 is associated with a greater risk for cardiovascular disease. In summary, by combining the results of pathway-specific GWASs and expression quantitative trait locus studies in humans with the results from platelet function studies in Grk5−/− mice, we obtain evidence that GRK5 regulates the human platelet response to thrombin via the PAR-1 pathway.
- 5 April 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (7) , 2319-2330
Open AccessG protein–coupled receptor kinase 5 regulates thrombin signaling in platelets via PAR-1
The interindividual variation in the functional response of platelets to activation by agonists is heritable. Genome-wide association studies (GWASs) of quantitative measures of platelet function have identified fewer than 20 distinctly associated variants, some with unknown mechanisms. Here, we report GWASs of pathway-specific functional responses to agonism by adenosine 5′-diphosphate, a glycoprotein VI–specific collagen mimetic, and thrombin receptor-agonist peptides, each specific to 1 of the G protein–coupled receptors PAR-1 and PAR-4, in subsets of 1562 individuals. We identified an association (P = 2.75 × 10−40) between a common intronic variant, rs10886430, in the G protein–coupled receptor kinase 5 gene (GRK5) and the sensitivity of platelets to activate through PAR-1. The variant resides in a megakaryocyte-specific enhancer that is bound by the transcription factors GATA1 and MEIS1. The minor allele (G) is associated with fewer GRK5 transcripts in platelets and the greater sensitivity of platelets to activate through PAR-1. We show that thrombin-mediated activation of human platelets causes binding of GRK5 to PAR-1 and that deletion of the mouse homolog Grk5 enhances thrombin-induced platelet activation sensitivity and increases platelet accumulation at the site of vascular injury. This corroborates evidence that the human G allele of rs10886430 is associated with a greater risk for cardiovascular disease. In summary, by combining the results of pathway-specific GWASs and expression quantitative trait locus studies in humans with the results from platelet function studies in Grk5−/− mice, we obtain evidence that GRK5 regulates the human platelet response to thrombin via the PAR-1 pathway.